Eris Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 20, 2026.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences' board has approved the acquisition of the branded probiotics business of Velbiom Probiotics Private Limited (VPPL) on a slump sale basis for a total consideration of Rs. 50 crore. The acquired portfolio includes prebiotic and probiotic formulations targeting metabolic health, gut wellness, and women's health. The target business generated revenues of Rs. 19.64 crore in FY25, Rs. 17.56 crore in FY24, and Rs. 16.02 crore in 9M FY26. The transaction is not a related-party deal, and no shares are being issued as consideration.
This is a bolt-on acquisition that strengthens Eris' presence in the probiotics and gut-health segment, adding incremental annual revenue of around Rs. 20 crore to its top line. At Rs. 50 crore for ~Rs. 20 crore of revenue, the deal is moderately priced and could support future growth, though its near-term impact on earnings and stock price is likely to be limited given the small size relative to Eris' overall business.